@prefix : <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix time: <http://www.w3.org/2006/time#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus> .

<http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus> rdf:type owl:Ontology ;
                                                                       owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ,
                                                                                   mp: ;
                                                                       rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255490/"^^xsd:anyURI ;
                                                                       rdfs:label "Denosumab and lichen planus"^^xsd:Literal ;
                                                                       owl:versionInfo "draft-v0.95-20211025"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Common_ASR_of_denosumab
:Common_ASR_of_denosumab rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Warning_Information ;
                         OpenPVSignal:refers_to_adverse_effect :musculoskeletalPain ,
                                                               :pain_in_the_extremity ;
                         OpenPVSignal:refers_to_drug :denosumab ;
                         mp:references :Ref.1 ;
                         rdfs:label "Common ADR of denosumab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#ConclusionContent
:ConclusionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Conclusion ;
                   OpenPVSignal:has_content "In summary, there are 14 reports associating LP with the use of denosumab. Denosumab was the only drug suspected in 12 of the 14 reports. Time to onset is consistent with a drug induced effect. Dechallenge is generally supportive of a drug association but for a drug such as denosumab, which is administered every six months, the concept of drug withdrawal is not meaningful. There appears to be a positive rechallenge in one case. It is possible that denosumab may cause LP using a similar mechanism to that of TNF-α inhibitors. " ;
                   rdfs:label "Conclusion content" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Denosumab_and_lichen_planus
:Denosumab_and_lichen_planus rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Pharmacovigilance_Signal_Report ;
                             OpenPVSignal:refers_to_author :Dr_Ian_Boyd ;
                             OpenPVSignal:refers_to_signal :pvSignal ;
                             OpenPVSignal:has_creation_date "01/12/2016" ;
                             OpenPVSignal:has_overall_conclusion "causal association probable" ;
                             rdfs:label "Denosumab and lichen planus" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#DiscussionContent
:DiscussionContent rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Discussion ;
                   mp:references :Ref.5 ,
                                 :Ref.6 ,
                                 :Ref.7 ,
                                 :Ref.8 ,
                                 :Ref.9 ;
                   OpenPVSignal:has_content "Case reports in VigiBase® suggest that there is a possible signal for the association of denosumab and LP. Denosumab was the only drug suspected in 12 of the 14 cases. Adalimumab and rituximab were co-suspected in the two remaining cases. The product literature for these two drugs also do not refer to LP.5,6 There is, however, a report in the literature of two cases of LP-like eruptions after infliximab and adalimumab therapy for psoriasis. The authors noted that in addition, at that time (2009), 11 cases of LP or lichenoid drug eruptions have been previously reported in patients taking tumour necrosis factor (TNF)-α inhibitors, in addition to several cases of psoriasiform eruptions with a lichenoid histology.7 In a more recent report, a case of toxic epidermal necrolysis treated with infliximab, which subsequently triggered erosive LP involving the mouth and vulva was described. The authors noted that LP and lichenoid eruptions are an emerging side effect of TNF-α antagonists, with 14 cases reported to date. Seven cases were associated with infliximab, with the others attributed to etanercept, adalimumab and lenercept.8 There have been no reports in association with rituximab. Time to onset was reported in seven of the reports and ranged from a few days to seven months after the drug was administered with a median of about 3-4 weeks. This would appear consistent with a drug induced effect. The outcome of the LP was stated in six of the 14 reports. All six patients were reported as recovered or recovering. In these patients, the drug was reported as withdrawn in four cases while the outcome of the drug was unknown in the remaining two cases. For a drug that is injected periodically, mostly every six months for denosumab, the effect of drug withdrawal or dechallenge is not meaningful. In one report (case 6), the patient had pre-existing LP which was apparently aggravated by denosumab. In another report (case 8), it is unclear whether the patient had pre-existing LP but it was reported that LP worsened after the first administration of denosumab, then recovered and then worsened again after the second administration. This appears to be a positive rechallenge. As indicated above, the cause of LP is not known and it is difficult to identify any patients in this case series who may be predisposed to LP. Lichenoid reactions, however, are known to occur as adverse reactions to drugs and this appears likely in these cases. As noted above, TNF-α inhibitors have been implicated in the induction of lichenoid reactions but because TNF-α has been implicated in the pathogenesis of LP, such induction is somewhat unexpected. It has been suggested that TNF-α inhibition may precipitate lichenoid reactions through disruption of a delicate balance between TNF-α and interferon-α in susceptible patients.7 Another suggested hypothesis is that the inhibition of TNF-α allows upregulation of other precursor pro-inflammatory cytokines, such as interferon-α, which causes activation of both T cells and dendritic cells.8 Since RANKL is a member of the TNF superfamily, it is possible that denosumab may cause LP through a similar mechanism.9 " ;
                   rdfs:label "Discussion content" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Dosage1
:Dosage1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Dosage ;
         OpenPVSignal:refers_to_drug :denosumab ;
         OpenPVSignal:refers_to_interval_between_administrations <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#6months-intervalBetweenAdministrations> ;
         OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
         OpenPVSignal:has_value 60 ;
         OpenPVSignal:refers_to_dose_value "60 mg" ;
         rdfs:label "Dosage 1" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Dosage2
:Dosage2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Dosage ;
         OpenPVSignal:refers_to_drug :denosumab ;
         OpenPVSignal:has_dosage_unit "mg"^^xsd:string ;
         OpenPVSignal:has_value 60 ;
         OpenPVSignal:refers_to_dose_value "60 mg" ;
         rdfs:label "Dosage 2" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Dosage_3
:Dosage_3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Dosage ;
          OpenPVSignal:refers_to_drug :denosumab ;
          OpenPVSignal:refers_to_interval_between_administrations <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#6months-intervalBetweenAdministrations> ;
          rdfs:label "Dosage 3" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Dr_Ian_Boyd
:Dr_Ian_Boyd rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Author ;
             OpenPVSignal:has_first_name "Ian" ;
             OpenPVSignal:has_last_name "Boyd" ;
             rdfs:label "Dr Ian Boyd" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Introduction_content
:Introduction_content rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Introduction ;
                      mp:references :Ref.1 ,
                                    :Ref.2 ,
                                    :Ref.3 ,
                                    :Ref.4 ;
                      OpenPVSignal:has_content "Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to the receptor activator of nuclear factor kappa-B ligand (RANKL), preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. Denosumab is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, and treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. The most common side effects with denosumab (seen in more than one patient in ten) are musculoskeletal pain and pain in the extremity. Uncommon cases of cellulitis; rare cases of hypocalcaemia, hypersensitivity, osteonecrosis of the jaw and atypical femoral fractures have been observed in patients taking denosumab.1 Lichen planus (LP) is a chronic mucocutaneous disease that affects the skin, tongue, and oral mucosa. The disease presents itself in the form of papules, lesions or rashes. The commonly affected sites are near the wrist and the ankle. The cause of LP is not known. While there are many theories to explain LP, it is believed it can be classified as an autoimmune disease.2,3 Some LP-type rashes (often referred to as lichenoid reactions) occur as adverse reactions to a variety of drugs including nonsteroidal anti-inflammatory drugs, anti-hypertensives such as angiotensin converting enzyme inhibitors and beta-blockers, tetracyclines, sulfonamides, penicillamine, allopurinol, gold, antibiotics, arsenic, iodides, chloroquine, quinidine, phenothiazines, and diuretics.3,4" ;
                      rdfs:label "Introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#LichenPlanus
:LichenPlanus rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Free_text_reporting_element ;
              OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
              mp:references :Ref.2 ,
                            :Ref.3 ;
              OpenPVSignal:has_content "Lichen planus (LP) is a chronic mucocutaneous disease that affects the skin, tongue, and oral mucosa. The disease presents itself in the form of papules, lesions or rashes. The commonly affected sites are near the wrist and the ankle. The cause of LP is not known. While there are many theories to explain LP, it is believed it can be classified as an autoimmune disease.2,3" ;
              rdfs:label "Lichen planus pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Lichen_planus_associated_with_a_variety_of_drugs
:Lichen_planus_associated_with_a_variety_of_drugs rdf:type owl:NamedIndividual ,
                                                           OpenPVSignal:Warning_Information ;
                                                  OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
                                                  OpenPVSignal:refers_to_class :angiotensinConvertingEnzymeInhibitors ,
                                                                               :anti-inflammatoryDrugs ,
                                                                               :antibiotics ,
                                                                               :beta-blockers ,
                                                                               :diuretics ,
                                                                               :iodides ,
                                                                               :phenothiazines ,
                                                                               :sulfonamides ,
                                                                               :tetracyclines ;
                                                  OpenPVSignal:refers_to_drug :allopurinol ,
                                                                              :arsenic ,
                                                                              :chloroquine ,
                                                                              :gold ,
                                                                              :penicillamine ,
                                                                              :quinidine ;
                                                  mp:references :Ref.3 ,
                                                                :Ref.4 ;
                                                  OpenPVSignal:has_content "Some LP-type rashes (often referred to as lichenoid reactions) occur as adverse reactions to a variety of drugs including nonsteroidal anti-inflammatory drugs, anti-hypertensives such as angiotensin converting enzyme inhibitors and beta-blockers, tetracyclines, sulfonamides, penicillamine, allopurinol, gold, antibiotics, arsenic, iodides, chloroquine, quinidine, phenothiazines, and diuretics.3,4" ;
                                                  rdfs:label "Lichen planus associated with a variety of drugs" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#LiteratureAndLabelling
:LiteratureAndLabelling rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Literature_information ;
                        mp:references :Ref.1 ;
                        OpenPVSignal:has_content "The product literature does not refer to LP but it notes that the skin reactions rash and eczema are common and that cases of cellulitis have been reported uncommonly.1 There are also no reports of LP in association with denosumab in the medical literature." ;
                        rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#MechanismOfDenosumab
:MechanismOfDenosumab rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Mechanism ;
                      mp:references :Ref.1 ;
                      OpenPVSignal:has_content "Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to the receptor activator of nuclear factor kappa-B ligand (RANKL), preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts.  Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. " ;
                      rdfs:label "Mechanism of denosumab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#NoReportedConnectionBetweenDenosumabAndLichenPlanus
:NoReportedConnectionBetweenDenosumabAndLichenPlanus rdf:type owl:NamedIndividual ,
                                                              OpenPVSignal:Warning_Information ;
                                                     OpenPVSignal:refers_to_adverse_effect :cellulitis ,
                                                                                           :eczema ,
                                                                                           :rash ;
                                                     OpenPVSignal:refers_to_drug :denosumab ;
                                                     mp:references :Ref.1 ;
                                                     OpenPVSignal:has_content "The product literature does not refer to LP but it notes that the skin reactions rash and eczema are common and that cases of cellulitis have been reported uncommonly.1 There are also no reports of LP in association with denosumab in the medical literature." ;
                                                     rdfs:label "Product literature for denosumab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#OverallReportsAfterTheEliminationOfDuplicates
:OverallReportsAfterTheEliminationOfDuplicates rdf:type owl:NamedIndividual ,
                                                        OpenPVSignal:Reports_group ;
                                               OpenPVSignal:is_subgroup_of :OverallReportsInVigibase ;
                                               OpenPVSignal:time_to_onset :timeToOnsetData ;
                                               OpenPVSignal:has_count 14 ;
                                               OpenPVSignal:has_count_of_women 13 ;
                                               OpenPVSignal:has_max_age 86 ;
                                               OpenPVSignal:has_median_age 69 ;
                                               OpenPVSignal:has_min_age 59 ;
                                               OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                               rdfs:label "Overall reports after the elimination of duplicates" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#OverallReportsInVigibase
:OverallReportsInVigibase rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Reports_group ;
                          OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
                          OpenPVSignal:refers_to_drug :denosumab ;
                          OpenPVSignal:has_count 18 ;
                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                          rdfs:label "Overall reports in vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 74 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 85 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient11
:Patient11 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient12
:Patient12 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 69 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient13
:Patient13 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 77 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 13" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient14
:Patient14 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 65 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 14" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient15
:Patient15 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 78 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 15" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient16
:Patient16 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 78 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 16" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient17
:Patient17 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 59 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 17" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient18
:Patient18 rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Patient ;
           OpenPVSignal:has_age 86 ;
           OpenPVSignal:has_gender "female" ;
           rdfs:label "Patient 18" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 68 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 64 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 66 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 78 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 66 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 72 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 71 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "European Medicines Agency. Summary ofproduct characteristics for Prolia. Availablefrom: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001120/WC500093526.pdf.Accessed: 3 February 2016." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "American Academy of Dermatology. Lichenplanus. Available from: http://www.aad.org/public/diseases/ rashes/lichen-planus.Accessed: 19 February 2016." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Medline Plus. Lichen planus. Available from:http://www.nlm.nih.gov/medlineplus/ency/article/000867.htm. Accessed: 19 February2016." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Sugerman PB, Savage NW. Oral lichenplanus: causes diagnosis and management.Aust Dental J 2002;47:290-7." ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Electronic Medicines Compendium. Summaryof Product Characteristics for Humira.Available from: http://www.medicines.org.uk/emc/medicine/21201. Accessed: 31 March2016." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Electronic Medicines Compendium. Summaryof Product Characteristics for Mabthera.Available from: http://www.medicines.org.uk/emc/medicine/2570. Accessed: 31 March2016." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Asarch A, Gottlieb AB, Lee J, Masterpol KS,Scheinman PL, Stadecker MJ, Massarotti EM,Bush ML. Lichen planus-like eruptions: anemerging side effect of tumor necrosis factor-α antagonists. JAAD 2009;61:104-11." ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Worsnop F, Wee J, Natkunarajah J, Moosa Y,Marsden R. Reaction to biological drugs:infliximab for the treatment of toxic epidermalnecrolysis subsequently triggering erosivelichen planus. Clin Exp Dermatol. 2012Dec;37(8):879-81." ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "Gaur U, Aggarwal BB. Regulation ofproliferation, survival and apoptosis bymembers of the TNF superfamily. BiochemPharmacol. 2003;66:1403-8." ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :gastrointestinalDisorder ,
                                               :lichen_planus ,
                                               :oralPain ,
                                               :stomatitisAphthous ;
         OpenPVSignal:refers_to_concomitant_drug :calcium ,
                                                 :colecalciferol ,
                                                 :lornoxicam ,
                                                 :panadolExtra ,
                                                 :pantoprazole ;
         OpenPVSignal:refers_to_patient :Patient1 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report10
:Report10 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :abdominalPain ,
                                                :abscess ,
                                                :abscessGenitalFemale ,
                                                :alopecia ,
                                                :appetiteLost ,
                                                :backPain ,
                                                :blisters ,
                                                :bodyHeightDecreased ,
                                                :burningSensation ,
                                                :cystitis ,
                                                :depressedMood ,
                                                :dermatitisLichenoid ,
                                                :discomfortBodily ,
                                                :erythema ,
                                                :eyeInflamed ,
                                                :heartburn ,
                                                :hiatusHernia ,
                                                :itching ,
                                                :lichen_planus ,
                                                :nausea ,
                                                :oralDisorder ,
                                                :oralPain ,
                                                :pain ,
                                                :popularRash ,
                                                :pruritus ,
                                                :rash ,
                                                :skinAtrophy ,
                                                :skinExfoliation ,
                                                :skinNodule ,
                                                :urinaryTractInfection ,
                                                :vaginalItching ,
                                                :vaginitis ,
                                                :vulvovaginalDiscomfort ,
                                                :weightDecrease ;
          OpenPVSignal:refers_to_concomitant_drug :lansoprazole ;
          OpenPVSignal:refers_to_patient :Patient10 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report11
:Report11 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :lichen_planus ,
                                                :pruritus ,
                                                :rashPsoriaform ,
                                                :urticaria ;
          OpenPVSignal:refers_to_concomitant_drug :acetylsalicylicAcid ,
                                                  :alfacalcidol ,
                                                  :atorvastatin ,
                                                  :calcium ,
                                                  :cyanocobalamin ,
                                                  :etanercept ,
                                                  :levothyroxine ,
                                                  :perindopril ;
          OpenPVSignal:refers_to_patient :Patient11 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_secondary_suspect_drug :adalimumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report12
:Report12 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :drugEruptionAggravated ,
                                                :lichen_planus ;
          OpenPVSignal:refers_to_concomitant_drug :calciumCarbonate ,
                                                  :ergocalciferol ;
          OpenPVSignal:refers_to_patient :Patient12 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_outcome_after_action "unknown" ;
          rdfs:label "Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report13
:Report13 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :itching ,
                                                :lichen_planus_aggravated ,
                                                :psoriasis ,
                                                :urticaria ;
          OpenPVSignal:refers_to_concomitant_drug :acetylsalicylicAcid ,
                                                  :alfacalcidol ,
                                                  :atorvastatin ,
                                                  :calcium ,
                                                  :cyanocobalamin ,
                                                  :etanercept ,
                                                  :levothyroxine ,
                                                  :perindopril ;
          OpenPVSignal:refers_to_patient :Patient13 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_secondary_suspect_drug :adalimumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report14
:Report14 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :gumPain ,
                                                :lichen_planus ,
                                                :skinReactionLocalisedAggravated ;
          OpenPVSignal:refers_to_concomitant_drug :calcium ,
                                                  :ergocalciferol ,
                                                  :levothyroxine ,
                                                  :lorazepam ,
                                                  :omeprazole ;
          OpenPVSignal:refers_to_patient :Patient14 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report15
:Report15 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :acanthosis ,
                                                :dermatitis ,
                                                :eczema ,
                                                :hyperkeratosis ,
                                                :keratosis ,
                                                :lichen_planus_aggravated ,
                                                :osteoporosis ,
                                                :rashPsoriaform ;
          OpenPVSignal:refers_to_concomitant_drug :acetylsalicylicAcid ,
                                                  :alfacalcidol ,
                                                  :atorvastatin ,
                                                  :cyanocobalamin ,
                                                  <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcarbonate/calciumLactateGluconate> ;
          OpenPVSignal:refers_to_patient :Patient15 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_secondary_suspect_drug :adalimumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 15" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report16
:Report16 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :lichen_planus_aggravated ,
                                                :psoriasis ;
          OpenPVSignal:refers_to_concomitant_drug :acetylsalicylicAcid ,
                                                  :alfacalcidol ,
                                                  :atorvastatin ,
                                                  :cyanocobalamin ,
                                                  <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcarbonate/calciumLactateGluconate> ;
          OpenPVSignal:refers_to_patient :Patient16 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_secondary_suspect_drug :adalimumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 16" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report17
:Report17 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
          OpenPVSignal:refers_to_patient :Patient17 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovering" ;
          rdfs:label "Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report18
:Report18 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:VigiBase_Report ;
          OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
          OpenPVSignal:refers_to_patient :Patient18 ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
          rdfs:label "Report 18" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :arthralgia ,
                                               :lichen_planus ,
                                               :myalgia ,
                                               :rash ;
         OpenPVSignal:refers_to_concomitant_drug :calcium ,
                                                 :ergocalciferol ,
                                                 :fishOil ,
                                                 <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#ascorbicacid/pyridoxinehydrochloride/biotin/tocopherylacetate/folicacid/cyanocobalamin/retinol/pantothenicacid/riboflavin/phytomenadione/nicotinamide/ferrousnfumarate/thiaminemononitrate/magnesiumoxide/zincoxide/cupricoxide/calcium/potassiumChloride> ;
         OpenPVSignal:refers_to_patient :Patient2 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
         OpenPVSignal:refers_to_patient :Patient3 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :anxiety ,
                                               :coughing ,
                                               :dysuria ,
                                               :headache ,
                                               :infectionLocalised ,
                                               :insomnia ,
                                               :lichen_planus ,
                                               :macularRash ,
                                               :pain ,
                                               :pruritus ,
                                               :pruritusAni ,
                                               :rash ,
                                               :sinusitis ,
                                               :vaginalDisorder ,
                                               :vaginalHaemorrhage ,
                                               :vulvovaginalRash ;
         OpenPVSignal:refers_to_concomitant_drug :alprazolam ,
                                                 :amitriptyline ,
                                                 :calcium ,
                                                 :calciumCarbonate ,
                                                 :fishOil ,
                                                 :fluoxetine ,
                                                 :guaifenesin ,
                                                 :iron ,
                                                 :levothyroxine ,
                                                 :macrogol3350 ,
                                                 :mometasone ,
                                                 :probiotic ,
                                                 :sumatriptan ,
                                                 <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcitrate/Magnesium> ;
         OpenPVSignal:refers_to_patient :Patient4 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
         OpenPVSignal:refers_to_patient :Patient5 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_free_text_reporting_element :report6 ;
         OpenPVSignal:refers_to_adverse_effect :acanthosis ,
                                               :dermatitis ,
                                               :eczema ,
                                               :hyperkeratosis ,
                                               :keratosis ,
                                               :lichen_planus_aggravated ,
                                               :osteoporosis ,
                                               :rashPsoriaform ;
         OpenPVSignal:refers_to_concomitant_drug :acetylsalicylicAcid ,
                                                 :alfacalcidol ,
                                                 :atorvastatin ,
                                                 :cyanocobalamin ,
                                                 <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcarbonate/calciumLactateGluconate> ;
         OpenPVSignal:refers_to_patient :Patient6 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_secondary_suspect_drug :adalimumab ;
         OpenPVSignal:refers_to_outcome_after_action "recovering" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report7
:Report7 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :anusDiscomfort ,
                                               :lichen_planus ,
                                               :pruritusAni ,
                                               :vulvaDisorder ;
         OpenPVSignal:refers_to_concomitant_drug :rituximab ;
         OpenPVSignal:refers_to_patient :Patient7 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report8
:Report8 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:has_free_text_reporting_element :report8 ;
         OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
         OpenPVSignal:refers_to_concomitant_drug :levothyroxine ,
                                                 :pantoprazole ,
                                                 :propranolol ;
         OpenPVSignal:refers_to_patient :Patient8 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         OpenPVSignal:refers_to_rechallenge_outcome "positive rechallenge - condition appeared again" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Report9
:Report9 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :eczema ,
                                               :goitre ,
                                               :lichen_planus ,
                                               :macule ,
                                               :rashPruritic ,
                                               :skinHyperpigmentation ,
                                               :skinSwelling ;
         OpenPVSignal:refers_to_concomitant_drug :amlodipine ,
                                                 :atorvastatin ,
                                                 :clopidogrel ,
                                                 :diazepam ,
                                                 :meclozine ,
                                                 :omeprazole ,
                                                 :quinapril ;
         OpenPVSignal:refers_to_patient :Patient9 ;
         OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Response_by_Amgen
:Response_by_Amgen rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Response_to_Pharmacovigilance_Signal_Report ;
                   OpenPVSignal:refers_to_pharmacovigilance_signal_report :Denosumab_and_lichen_planus ;
                   OpenPVSignal:has_content "Amgen acknowledges that cases of lichen planus have been reported. As part of ongoing pharmacovigilance activities, Amgen has previously conducted a comprehensive safety assessment to evaluate the risk of lichen planus with the use of denosumab and reported the results in Periodic Benefit-Risk Evaluation Report/Periodic Safety Update Report Number 8. For evaluation of this safety signal, Amgen utilized a cumulative review of all study and nonstudy adverse event reports with denosumab as well as a review of the epidemiology data with lichen planus, nonclinical data and controlled clinical trial data. Biological plausibility was also assessed. Based upon the comprehensive review, no new safety risk was identified for lichen planus with the use of denosumab. The Amgen conclusion to close the signal lichen planus was endorsed by the Pharmacovigilance Risk Assessment Committee (dated 10 April 2015). The benefit:risk profile of denosumab remains favourable in the current approved indications and the product label adequately reflects the safety profile of Prolia. Amgen will continue to monitor events of lichen planus through ongoing routine pharmacovigilance activities." ;
                   rdfs:label "Response by Amgen" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Subcutaneous_administration
:Subcutaneous_administration rdf:type owl:NamedIndividual ,
                                      OpenPVSignal:Drug_Intake_Form ;
                             OpenPVSignal:refers_to_drug :denosumab ;
                             OpenPVSignal:refers_to_form_of_intake "subcutaneous" ;
                             rdfs:label "Subcutaneous administration" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#SummaryContent
:SummaryContent rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Summary ;
                OpenPVSignal:has_content "Denosumab and lichen planus Dr Ian Boyd, Australia Summary Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to the receptor activator of nuclear factor kappa-B ligand (RANKL), preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. Denosumab is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, and treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. After the elimination of suspected duplicates there are (as of 1 January 2016) 14 individual case safety reports in the WHO Global ICSR database, VigiBase®, of lichen planus (LP) in association with denosumab. The reports are from Canada, Denmark, Greece, the Netherlands, Serbia, Switzerland, and the United States. Denosumab was the only drug suspected in 12 of the 14 cases. The outcome of the LP was stated in six of the 14 reports. All six patients were reported as recovered or recovering. In these patients, the drug was reported as withdrawn in four cases while the outcome of the drug was unknown in the remaining two cases. Case reports in VigiBase® suggest that there is a possible signal for the association of denosumab and LP. Time to onset is consistent with a drug induced effect. Dechallenge is generally supportive of a drug association but for a drug such as denosumab, which is administered every six months, the concept of drug withdrawal is not meaningful. There appears to be a positive rechallenge in one case. It is possible that denosumab may cause LP using a similar mechanism to that of TNF-α inhibitors. " ;
                rdfs:label "Summary content" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Uncommon_ADR_of_denosumab
:Uncommon_ADR_of_denosumab rdf:type owl:NamedIndividual ,
                                    OpenPVSignal:Warning_Information ;
                           OpenPVSignal:refers_to_adverse_effect :atypicalFemoralFractures ,
                                                                 :cellulitis ,
                                                                 :hypersensitivity ,
                                                                 :hypocalcaemia ,
                                                                 :osteonecrosisOfTheJaw ;
                           OpenPVSignal:refers_to_drug :denosumab ;
                           mp:references :Ref.1 ;
                           rdfs:label "Uncommon ADR of denosumab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#Usage_of_denosumab
:Usage_of_denosumab rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug_Usage ;
                    OpenPVSignal:concerns_indication_for_use :boneLoss ,
                                                             :osteoporosis ;
                    OpenPVSignal:refers_to_drug :denosumab ;
                    OpenPVSignal:has_content "Denosumab is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, and treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures." ;
                    rdfs:label "Usage of denosumab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#abdominalPain
:abdominalPain rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "R10.9" ;
               OpenPVSignal:has_MedDRA_code 10000081 ;
               OpenPVSignal:has_MedDRA_prefered_term "Abdominal pain" ;
               rdfs:label "abdominal pain" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#abscess
:abscess rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10000269 ;
         OpenPVSignal:has_MedDRA_prefered_term "Abscess" ;
         rdfs:label "abscess" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#abscessGenitalFemale
:abscessGenitalFemale rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Adverse_Effect ;
                      OpenPVSignal:has_ICD_code "N76.4" ;
                      OpenPVSignal:has_MedDRA_code 10049573 ;
                      OpenPVSignal:has_MedDRA_prefered_term "Vaginal abscess" ;
                      rdfs:label "abscess genital female" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#acanthosis
:acanthosis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "L83" ;
            OpenPVSignal:has_MedDRA_code 10000349 ;
            OpenPVSignal:has_MedDRA_prefered_term "Acanthosis" ;
            rdfs:label "acanthosis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#acetylsalicylicAcid
:acetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Drug ;
                     OpenPVSignal:has_ATC_code "B01AC06" ;
                     rdfs:label "acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#adalimumab
:adalimumab rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AB04" ;
            rdfs:label "adalimumab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#alfacalcidol
:alfacalcidol rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A11CC03" ;
              rdfs:label "alfacalcidol" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#allopurinol
:allopurinol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "M04AA01" ;
             rdfs:label "allopurinol" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#alopecia
:alopecia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "L65.9" ;
          OpenPVSignal:has_MedDRA_code 10001760 ;
          OpenPVSignal:has_MedDRA_prefered_term "Alopecia" ;
          rdfs:label "alopecia" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#alprazolam
:alprazolam rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N05BA12" ;
            rdfs:label "alprazolam" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#amitriptyline
:amitriptyline rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "N06AA09" ;
               rdfs:label "amitriptyline" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#amlodipine
:amlodipine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "C08CA01" ;
            rdfs:label "amlodipine" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#angiotensinConvertingEnzymeInhibitors
:angiotensinConvertingEnzymeInhibitors rdf:type owl:NamedIndividual ,
                                                OpenPVSignal:DrugClass ;
                                       OpenPVSignal:has_ATC_code "C09AA " ;
                                       rdfs:label "angiotensin converting enzyme inhibitors" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#anti-inflammatoryDrugs
:anti-inflammatoryDrugs rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:DrugClass ;
                        OpenPVSignal:has_ATC_code "M01 " ;
                        rdfs:label "anti-inflammatory drugs" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#antibiotics
:antibiotics rdf:type owl:NamedIndividual ,
                      OpenPVSignal:DrugClass ;
             OpenPVSignal:has_ATC_code "A07AA " ;
             rdfs:label "antibiotics" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#anusDiscomfort
:anusDiscomfort rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "K62.89" ;
                OpenPVSignal:has_MedDRA_code 10002851 ;
                OpenPVSignal:has_MedDRA_prefered_term "Anus discomfort" ;
                rdfs:label "anus discomfort" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#anxiety
:anxiety rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "F41.9" ;
         OpenPVSignal:has_MedDRA_code 10002855 ;
         OpenPVSignal:has_MedDRA_prefered_term "Anxiety" ;
         rdfs:label "anxiety" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#appetiteLost
:appetiteLost rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "R63.0" ;
              OpenPVSignal:has_MedDRA_code 10061428 ;
              OpenPVSignal:has_MedDRA_prefered_term "Decreased appetite" ;
              rdfs:label "appetite lost" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#arsenic
:arsenic rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug ;
         OpenPVSignal:has_ATC_code "L01XX27" ;
         rdfs:label "arsenic" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#arthralgia
:arthralgia rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code " M26.62" ;
            OpenPVSignal:has_MedDRA_code 10003239 ;
            OpenPVSignal:has_MedDRA_prefered_term "Arthralgia" ;
            rdfs:label "arthralgia" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#atorvastatin
:atorvastatin rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "C10AA05" ;
              rdfs:label "atorvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#atypicalFemoralFractures
:atypicalFemoralFractures rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_ICD_code "M84.750A" ;
                          OpenPVSignal:has_MedDRA_code 10070884 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Atypical femur fracture" ;
                          rdfs:label "atypical femoral fractures " .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#backPain
:backPain rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_MedDRA_code 10003988 ;
          OpenPVSignal:has_MedDRA_prefered_term "Back pain" ;
          rdfs:label "back pain" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#beta-blockers
:beta-blockers rdf:type owl:NamedIndividual ,
                        OpenPVSignal:DrugClass ;
               OpenPVSignal:has_ATC_code "C07A " ;
               rdfs:label "beta-blockers" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#blisters
:blisters rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "S90.821A" ;
          OpenPVSignal:has_MedDRA_code 10005191 ;
          OpenPVSignal:has_MedDRA_prefered_term "Blister" ;
          rdfs:label "blisters" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#bodyHeightDecreased
:bodyHeightDecreased rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "R29.890" ;
                     OpenPVSignal:has_MedDRA_code 10056812 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Body height decreased" ;
                     rdfs:label "body height decreased" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#boneLoss
:boneLoss rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Indication ;
          OpenPVSignal:has_ICD_code "M85.9" ;
          OpenPVSignal:has_MedDRA_code 10065687 ;
          OpenPVSignal:has_MedDRA_prefered_term "Bone loss" ;
          rdfs:label "bone loss" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#burningSensation
:burningSensation rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "R20.8" ;
                  OpenPVSignal:has_MedDRA_code 10006784 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Burning sensation" ;
                  rdfs:label "burning sensation" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calcium
:calcium rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug ;
         OpenPVSignal:has_ATC_code "A12AA" ;
         rdfs:label "calcium" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumCarbonate
:calciumCarbonate rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Drug ;
                  OpenPVSignal:has_ATC_code "A12AA04 " ;
                  rdfs:label "calcium carbonate" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#cellulitis
:cellulitis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "L03.90" ;
            OpenPVSignal:has_MedDRA_code 10007882 ;
            OpenPVSignal:has_MedDRA_prefered_term "Cellulitis" ;
            rdfs:label "cellulitis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#chloroquine
:chloroquine rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "P01BA01" ;
             rdfs:label "chloroquine" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#clopidogrel
:clopidogrel rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "B01AC04" ;
             rdfs:label "clopidogrel" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#colecalciferol
:colecalciferol rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "A11CC05" ;
                rdfs:label "colecalciferol" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#coughing
:coughing rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R05" ;
          OpenPVSignal:has_MedDRA_code 10011224 ;
          OpenPVSignal:has_MedDRA_prefered_term "Cough" ;
          rdfs:label "coughing" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#cyanocobalamin
:cyanocobalamin rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "B03BA0" ;
                rdfs:label "cyanocobalamin" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#cystitis
:cystitis rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "N30.90" ;
          OpenPVSignal:has_MedDRA_code 10011781 ;
          OpenPVSignal:has_MedDRA_prefered_term "Cystitis" ;
          rdfs:label "cystitis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#denosumab
:denosumab rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_mechanism :MechanismOfDenosumab ,
                                      :possibleMechanismForLichenPlanusByDenosumab ;
           OpenPVSignal:has_ATC_code "M05BX04" ;
           rdfs:label "denosumab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#denosumab_usage_for_reports_with_dosage_information
:denosumab_usage_for_reports_with_dosage_information rdf:type owl:NamedIndividual ,
                                                              OpenPVSignal:Drug_Usage ;
                                                     OpenPVSignal:refers_to_dosage :Dosage1 ;
                                                     OpenPVSignal:refers_to_drug :denosumab ;
                                                     rdfs:label "usage for dosage 1" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#denosumab_usage_for_reports_with_dosage_information_1
:denosumab_usage_for_reports_with_dosage_information_1 rdf:type owl:NamedIndividual ,
                                                                OpenPVSignal:Drug_Usage ;
                                                       OpenPVSignal:refers_to_dosage :Dosage2 ;
                                                       OpenPVSignal:refers_to_drug :denosumab ;
                                                       rdfs:label "usage for dosage 2" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#depressedMood
:depressedMood rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "F32" ;
               OpenPVSignal:has_MedDRA_code 10012374 ;
               OpenPVSignal:has_MedDRA_prefered_term "Depressed mood" ;
               rdfs:label "depressed mood" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#dermatitis
:dermatitis rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_ICD_code "L30.9" ;
            OpenPVSignal:has_MedDRA_code 10012431 ;
            OpenPVSignal:has_MedDRA_prefered_term "Dermatitis" ;
            rdfs:label "dermatitis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#dermatitisLichenoid
:dermatitisLichenoid rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_MedDRA_code 10012472 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Dermatitis lichenoid" ;
                     rdfs:label "dermatitis lichenoid" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#diazepam
:diazepam rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Drug ;
          OpenPVSignal:has_ATC_code "N05BA01" ;
          rdfs:label "diazepam" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#discomfortBodily
:discomfortBodily rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_MedDRA_code 10013086 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Discomfort bodily" ;
                  rdfs:label "discomfort bodily" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#diuretics
:diuretics rdf:type owl:NamedIndividual ,
                    OpenPVSignal:DrugClass ;
           OpenPVSignal:has_ATC_code "C03 " ;
           rdfs:label "diuretics" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#drugEruptionAggravated
:drugEruptionAggravated rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_MedDRA_code 10013687 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Drug eruption" ;
                        rdfs:label "drug eruption" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#dysuria
:dysuria rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "R30.0" ;
         OpenPVSignal:has_MedDRA_code 10013990 ;
         OpenPVSignal:has_MedDRA_prefered_term "Dysuria" ;
         rdfs:label "dysuria" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#eczema
:eczema rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_MedDRA_code 10014184 ;
        OpenPVSignal:has_MedDRA_prefered_term "Eczema" ;
        rdfs:label "eczema" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#ergocalciferol
:ergocalciferol rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Drug ;
                OpenPVSignal:has_ATC_code "A11CC01" ;
                rdfs:label "ergocalciferol" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#erythema
:erythema rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "L53.9" ;
          OpenPVSignal:has_MedDRA_code 10015150 ;
          OpenPVSignal:has_MedDRA_prefered_term "Erythema" ;
          rdfs:label "erythema" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#etanercept
:etanercept rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AB01" ;
            rdfs:label "etanercept" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#eyeInflamed
:eyeInflamed rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "H01.9" ;
             OpenPVSignal:has_MedDRA_code 10015943 ;
             OpenPVSignal:has_MedDRA_prefered_term "Eye inflammation" ;
             rdfs:label "eye inflamed" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#fishOil
:fishOil rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug ;
         OpenPVSignal:has_ATC_code "C10AX06 " ;
         rdfs:label "fish oil" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#fluoxetine
:fluoxetine rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "N06AB03" ;
            rdfs:label "fluoxetine" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#gastrointestinalDisorder
:gastrointestinalDisorder rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_ICD_code "K92.9" ;
                          OpenPVSignal:has_MedDRA_code 10017944 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal disorder" ;
                          rdfs:label "gastrointestinal disorder" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#goitre
:goitre rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_ICD_code "E04.9" ;
        OpenPVSignal:has_MedDRA_code 10018498 ;
        OpenPVSignal:has_MedDRA_prefered_term "Goitre" ;
        rdfs:label "goitre" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#gold
:gold rdf:type owl:NamedIndividual ,
               OpenPVSignal:Drug ;
      OpenPVSignal:has_ATC_code "M01CB" ;
      rdfs:label "gold" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#guaifenesin
:guaifenesin rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "R05CA03" ;
             rdfs:label "guaifenesin" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#gumPain
:gumPain rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10018787 ;
         OpenPVSignal:has_MedDRA_prefered_term "Gum pain" ;
         rdfs:label "gum pain" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#headache
:headache rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R51" ;
          OpenPVSignal:has_MedDRA_code 10019211 ;
          OpenPVSignal:has_MedDRA_prefered_term "Headache" ;
          rdfs:label "headache" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#heartburn
:heartburn rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10019326 ;
           OpenPVSignal:has_MedDRA_prefered_term "Heartburn" ;
           rdfs:label "heartburn" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#hiatusHernia
:hiatusHernia rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "K44.9" ;
              OpenPVSignal:has_MedDRA_code 10020028 ;
              OpenPVSignal:has_MedDRA_prefered_term "Hiatus hernia" ;
              rdfs:label "hiatus hernia" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#hyperkeratosis
:hyperkeratosis rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "L85.9" ;
                OpenPVSignal:has_MedDRA_code 10020649 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hyperkeratosis" ;
                rdfs:label "hyperkeratosis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#hypersensitivity
:hypersensitivity rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "T78.40XA" ;
                  OpenPVSignal:has_MedDRA_code 10020751 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Hypersensitivity" ;
                  rdfs:label "hypersensitivity" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#hypocalcaemia
:hypocalcaemia rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "E83.51" ;
               OpenPVSignal:has_MedDRA_code 10020947 ;
               OpenPVSignal:has_MedDRA_prefered_term "Hypocalcemia" ;
               rdfs:label "hypocalcaemia" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#infectionLocalised
:infectionLocalised rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10024774 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Localised infection" ;
                    rdfs:label "infection localised" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#infliximab
:infliximab rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "L04AB02 " ;
            rdfs:label "infliximab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#insomnia
:insomnia rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "G47.0" ;
          OpenPVSignal:has_MedDRA_code 10022437 ;
          OpenPVSignal:has_MedDRA_prefered_term "Insomnia" ;
          rdfs:label "insomnia" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#iodides
:iodides rdf:type owl:NamedIndividual ,
                  OpenPVSignal:DrugClass ;
         OpenPVSignal:has_ATC_code "V10XA " ;
         rdfs:label "iodides" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#iron
:iron rdf:type owl:NamedIndividual ,
               OpenPVSignal:Drug ;
      OpenPVSignal:has_ATC_code "B03A" ;
      rdfs:label "iron" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#itching
:itching rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_MedDRA_code 10023084 ;
         OpenPVSignal:has_MedDRA_prefered_term "Itching" ;
         rdfs:label "itching" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#keratosis
:keratosis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_MedDRA_code 10023368 ;
           OpenPVSignal:has_MedDRA_prefered_term "Keratosis" ;
           rdfs:label "keratosis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#lansoprazole
:lansoprazole rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A02BC03" ;
              rdfs:label "lansoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#levothyroxine
:levothyroxine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "H03AA01" ;
               rdfs:label "levothyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#lichen_planus
:lichen_planus rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "L43.9" ;
               OpenPVSignal:has_MedDRA_code 10024429 ;
               OpenPVSignal:has_MedDRA_prefered_term "Lichen planus" ;
               rdfs:label "lichen planus" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#lichen_planus_aggravated
:lichen_planus_aggravated rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_MedDRA_code 10024430 ;
                          OpenPVSignal:has_MedDRA_prefered_term "Lichen planus aggravated" ;
                          rdfs:label "lichen planus aggravated" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#literature_report
:literature_report rdf:type owl:NamedIndividual ,
                            obo:OAE_0001125 ;
                   OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
                   OpenPVSignal:refers_to_drug :adalimumab ,
                                               :infliximab ;
                   mp:references :Ref.7 ;
                   OpenPVSignal:has_content "There is, however, a report in the literature of two cases of LP-like eruptions after infliximab and adalimumab therapy for psoriasis. The authors noted that in addition, at that time (2009), 11 cases of LP or lichenoid drug eruptions have been previously reported in patients taking tumour necrosis factor (TNF)-α inhibitors, in addition to several cases of psoriasiform eruptions with a lichenoid histology.7" ;
                   rdfs:label "literature report" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#lorazepam
:lorazepam rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "N05BA06" ;
           rdfs:label "lorazepam" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#lornoxicam
:lornoxicam rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "M01AC05" ;
            rdfs:label "lornoxicam" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#macrogol3350
:macrogol3350 rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A06AD15" ;
              rdfs:label "macrogol" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#macularRash
:macularRash rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "R21" ;
             OpenPVSignal:has_MedDRA_code 10037867 ;
             OpenPVSignal:has_MedDRA_prefered_term "Rash macular" ;
             rdfs:label "macular rash" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#macule
:macule rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_ICD_code "L98.8" ;
        OpenPVSignal:has_MedDRA_code 10025421 ;
        OpenPVSignal:has_MedDRA_prefered_term "Macule" ;
        rdfs:label "macule" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#meclozine
:meclozine rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "R06AE05" ;
           rdfs:label "meclozine" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#mometasone
:mometasone rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "R01AD09" ;
            rdfs:label "mometasone" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#more_recent_report
:more_recent_report rdf:type owl:NamedIndividual ,
                             obo:OAE_0001125 ;
                    OpenPVSignal:refers_to_adverse_effect :lichen_planus ,
                                                          :toxicEpidermalNecrolysis ;
                    OpenPVSignal:refers_to_drug :infliximab ;
                    mp:references :Ref.8 ;
                    OpenPVSignal:has_content "In a more recent report, a case of toxic epidermal necrolysis treated with infliximab, which subsequently triggered erosive LP involving the mouth and vulva was described. The authors noted that LP and lichenoid eruptions are an emerging side effect of TNF-α antagonists, with 14 cases reported to date. Seven cases were associated with infliximab, with the others attributed to etanercept, adalimumab and lenercept.8" ;
                    rdfs:label "more recent report" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#musculoskeletalPain
:musculoskeletalPain rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Adverse_Effect ;
                     OpenPVSignal:has_ICD_code "M79. 10" ;
                     OpenPVSignal:has_MedDRA_code 10028391 ;
                     OpenPVSignal:has_MedDRA_prefered_term "Musculoskeletal pain" ;
                     rdfs:label "musculoskeletal pain " .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#myalgia
:myalgia rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Adverse_Effect ;
         OpenPVSignal:has_ICD_code "M79.1" ;
         OpenPVSignal:has_MedDRA_code 10028411 ;
         OpenPVSignal:has_MedDRA_prefered_term "Myalgia" ;
         rdfs:label "myalgia" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#nausea
:nausea rdf:type owl:NamedIndividual ,
                 OpenPVSignal:Adverse_Effect ;
        OpenPVSignal:has_ICD_code "R11" ;
        OpenPVSignal:has_MedDRA_code 10028813 ;
        OpenPVSignal:has_MedDRA_prefered_term "Nausea" ;
        rdfs:label "nausea" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#omeprazole
:omeprazole rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:has_ATC_code "A02BC01" ;
            rdfs:label "omeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#oralDisorder
:oralDisorder rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_MedDRA_code 10067621 ;
              OpenPVSignal:has_MedDRA_prefered_term "Oral disorder" ;
              rdfs:label "oral disorder" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#oralPain
:oralPain rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "K08.89" ;
          OpenPVSignal:has_MedDRA_code 10031009 ;
          OpenPVSignal:has_MedDRA_prefered_term "Oral pain" ;
          rdfs:label "oral pain" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#osteonecrosisOfTheJaw
:osteonecrosisOfTheJaw rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_MedDRA_code 10064658 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Osteonecrosis of jaw" ;
                       rdfs:label "osteonecrosis of the jaw" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#osteoporosis
:osteoporosis rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ,
                       OpenPVSignal:Indication ;
              OpenPVSignal:has_ICD_code "M81.0" ;
              OpenPVSignal:has_MedDRA_code 10031282 ;
              OpenPVSignal:has_MedDRA_prefered_term "Osteoporosis" ;
              rdfs:label "osteoporosis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#pain
:pain rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_ICD_code "G89.1" ;
      OpenPVSignal:has_MedDRA_code 10033371 ;
      OpenPVSignal:has_MedDRA_prefered_term "Pain" ;
      rdfs:label "pain" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#pain_in_the_extremity
:pain_in_the_extremity rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_ICD_code "M79.606" ;
                       OpenPVSignal:has_MedDRA_code 10033425 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Pain in extremity" ;
                       rdfs:label "pain in the extremity" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#panadolExtra
:panadolExtra rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "N02BE51" ;
              rdfs:label "panadol extra" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#pantoprazole
:pantoprazole rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A02BC02" ;
              rdfs:label "pantoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#penicillamine
:penicillamine rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Drug ;
               OpenPVSignal:has_ATC_code "M01CC01" ;
               rdfs:label "penicillamine" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#perindopril
:perindopril rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "C09AA04" ;
             rdfs:label "perindopril" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#phenothiazines
:phenothiazines rdf:type owl:NamedIndividual ,
                         OpenPVSignal:DrugClass ;
                OpenPVSignal:has_ATC_code "N05AA " ;
                rdfs:label "phenothiazines" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#popularRash
:popularRash rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "R21" ;
             OpenPVSignal:has_MedDRA_code 10037844 ;
             OpenPVSignal:has_MedDRA_prefered_term "Rash" ;
             rdfs:label "popular rash" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#possibleMechanismForLichenPlanusByDenosumab
:possibleMechanismForLichenPlanusByDenosumab rdf:type owl:NamedIndividual ,
                                                      OpenPVSignal:Adverse_Effect_Mechanism ;
                                             OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
                                             OpenPVSignal:refers_to_class :tnf-aAntagonists ;
                                             mp:references :Ref.7 ,
                                                           :Ref.8 ,
                                                           :Ref.9 ;
                                             OpenPVSignal:has_content "It has been suggested that TNF-α inhibition may precipitate lichenoid reactions through disruption of a delicate balance between TNF-α and interferon-α in susceptible patients .7 Another suggested hypothesis is that the inhibition of TNF-α allows upregulation of other precursor pro-inflammatory cytokines, such as interferon-α, which causes activation of both T cells and dendritic cells.8 Since RANKL is a member of the TNF superfamily, it is possible that denosumab may cause LP through a similar mechanism " ;
                                             rdfs:label "possible mechanism for lichen planus by denosumab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#probiotic
:probiotic rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "QA07FA90" ;
           rdfs:label "probiotic" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#propranolol
:propranolol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "C07AA05" ;
             rdfs:label "propranolol" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#pruritus
:pruritus rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "L29" ;
          OpenPVSignal:has_MedDRA_code 10037087 ;
          OpenPVSignal:has_MedDRA_prefered_term "Pruritus" ;
          rdfs:label "pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#pruritusAni
:pruritusAni rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10037089 ;
             OpenPVSignal:has_MedDRA_prefered_term "Pruritus ani" ;
             rdfs:label "pruritus ani" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#psoriasis
:psoriasis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "L40" ;
           OpenPVSignal:has_MedDRA_code 10037153 ;
           OpenPVSignal:has_MedDRA_prefered_term "Psoriasis" ;
           rdfs:label "psoriasis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :ConclusionContent ,
                                                   :DiscussionContent ,
                                                   :Introduction_content ,
                                                   :LichenPlanus ,
                                                   :SummaryContent ,
                                                   <http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#ReportsInVigiBase®> ;
          OpenPVSignal:is_supported_by_individual_case_report :Report1 ,
                                                              :Report10 ,
                                                              :Report11 ,
                                                              :Report12 ,
                                                              :Report13 ,
                                                              :Report14 ,
                                                              :Report15 ,
                                                              :Report16 ,
                                                              :Report17 ,
                                                              :Report18 ,
                                                              :Report2 ,
                                                              :Report3 ,
                                                              :Report4 ,
                                                              :Report5 ,
                                                              :Report6 ,
                                                              :Report7 ,
                                                              :Report8 ,
                                                              :Report9 ;
          OpenPVSignal:is_supported_by_statistical_entity :OverallReportsAfterTheEliminationOfDuplicates ,
                                                          :OverallReportsInVigibase ,
                                                          :reportsFromCanada ,
                                                          :reportsFromDenmark ,
                                                          :reportsFromGreece ,
                                                          :reportsFromNetherlands ,
                                                          :reportsFromSerbia ,
                                                          :reportsFromSwitzerland ,
                                                          :reportsFromUS ,
                                                          :reportsWithDenosumabAsTheSuspectedDrug ,
                                                          :reports_with_dermatitis ,
                                                          :reports_with_dosage_2 ,
                                                          :reports_with_dosage_3 ,
                                                          :reports_with_dosage_information ,
                                                          :reports_with_pruritus ,
                                                          :reports_with_rashes ,
                                                          :reports_with_recovery_after_drug_withdrawl ,
                                                          :reports_with_recovery_without_any_info ,
                                                          :reports_with_subcutaneous_administration ;
          OpenPVSignal:refers_to_adverse_effect :lichen_planus ;
          OpenPVSignal:refers_to_drug :denosumab ;
          OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
          mp:supportedByData :Common_ASR_of_denosumab ,
                             :Lichen_planus_associated_with_a_variety_of_drugs ,
                             :NoReportedConnectionBetweenDenosumabAndLichenPlanus ,
                             :Uncommon_ADR_of_denosumab ,
                             :literature_report ,
                             :more_recent_report ;
          OpenPVSignal:initially_identified_on "01/12/2016" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#quinapril
:quinapril rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "C09AA06" ;
           rdfs:label "quinapril" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#quinidine
:quinidine rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "C01BA01" ;
           rdfs:label "quinidine" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#rash
:rash rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_ICD_code "R21" ;
      OpenPVSignal:has_MedDRA_code 10037844 ;
      OpenPVSignal:has_MedDRA_prefered_term "Rash" ;
      rdfs:label "rash" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#rashPruritic
:rashPruritic rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "L29.9" ;
              OpenPVSignal:has_MedDRA_code 10037884 ;
              OpenPVSignal:has_MedDRA_prefered_term "Rash pruritic" ;
              rdfs:label "rash pruritic" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#rashPsoriaform
:rashPsoriaform rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10037885 ;
                OpenPVSignal:has_MedDRA_prefered_term "Rash psoriaform" ;
                rdfs:label "rash psoriaform" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#report6
:report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Case_Report_Information ;
         OpenPVSignal:has_content "In one report (case 6), the patient had pre-existing LP which was apparently aggravated by denosumab. " ;
         rdfs:label "case 6 info" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#report8
:report8 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Case_Report_Information ;
         OpenPVSignal:has_content "In another report (case 8), it is unclear whether the patient had pre-existing LP but it was reported that LP worsened after the first administration of denosumab, then recovered and then worsened again after the second administration. This appears to be a positive rechallenge" ;
         rdfs:label "case 8 info" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reportsFromCanada
:reportsFromCanada rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                   OpenPVSignal:has_count 1 ;
                   OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Canada" ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "reports from Canada" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reportsFromDenmark
:reportsFromDenmark rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                    OpenPVSignal:has_count 1 ;
                    OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Denmark" ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "reports from Denmark" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reportsFromGreece
:reportsFromGreece rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                   OpenPVSignal:has_count 1 ;
                   OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Greece" ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "reports from Greece" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reportsFromNetherlands
:reportsFromNetherlands rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                        OpenPVSignal:has_count 1 ;
                        OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Netherlands" ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        rdfs:label "reports from Netherlands" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reportsFromSerbia
:reportsFromSerbia rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Reports_group ;
                   OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                   OpenPVSignal:has_count 1 ;
                   OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Serbia" ;
                   OpenPVSignal:refers_to_database "WHO Vigibase" ;
                   rdfs:label "reports from Serbia" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reportsFromSwitzerland
:reportsFromSwitzerland rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Reports_group ;
                        OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                        OpenPVSignal:has_count 1 ;
                        OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Switzerland" ;
                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                        rdfs:label "reports from Switzerland" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reportsFromUS
:reportsFromUS rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Reports_group ;
               OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
               OpenPVSignal:has_count 8 ;
               OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
               OpenPVSignal:refers_to_database "WHO Vigibase" ;
               rdfs:label "reports from US" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reportsWithDenosumabAsTheSuspectedDrug
:reportsWithDenosumabAsTheSuspectedDrug rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Reports_group ;
                                        OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                                        OpenPVSignal:refers_to_primary_suspect_drug :denosumab ;
                                        OpenPVSignal:has_count 12 ;
                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                        rdfs:label "reports with denosumab  as the suspected drug" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_dermatitis
:reports_with_dermatitis rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                         OpenPVSignal:refers_to_adverse_effect :dermatitis ,
                                                               :eczema ,
                                                               :skinReactionLocalisedAggravated ;
                         OpenPVSignal:has_count 4 ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         rdfs:label "reports with dermatitis, eczema or another skin reaction" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_dosage_2
:reports_with_dosage_2 rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Reports_group ;
                       OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                       OpenPVSignal:refers_to_reported_drug_usage :denosumab_usage_for_reports_with_dosage_information_1 ;
                       OpenPVSignal:has_count 4 ;
                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                       rdfs:label "reports with dosage 2" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_dosage_3
:reports_with_dosage_3 rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Reports_group ;
                       OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                       OpenPVSignal:refers_to_reported_drug_usage :usage_for_dosage_3 ;
                       OpenPVSignal:has_count 2 ;
                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                       rdfs:label "reports with dosage 3" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_dosage_information
:reports_with_dosage_information rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                                 OpenPVSignal:refers_to_reported_drug_usage :denosumab_usage_for_reports_with_dosage_information ;
                                 OpenPVSignal:has_count 3 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "reports with dosage 1" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_pruritus
:reports_with_pruritus rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Reports_group ;
                       OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                       OpenPVSignal:refers_to_adverse_effect :pruritus ;
                       OpenPVSignal:has_count 3 ;
                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                       rdfs:label "reports with pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_rashes
:reports_with_rashes rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Reports_group ;
                     OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                     OpenPVSignal:refers_to_adverse_effect :rash ;
                     OpenPVSignal:has_count 5 ;
                     OpenPVSignal:refers_to_database "WHO Vigibase" ;
                     rdfs:label "reports with rashes" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_recovery_after_drug_withdrawl
:reports_with_recovery_after_drug_withdrawl rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Reports_group ;
                                            OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                                            OpenPVSignal:has_count 4 ;
                                            OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                            OpenPVSignal:refers_to_outcome_after_action "recovery after drug withdrawal" ;
                                            rdfs:label "reports with recovery after drug withdrawl" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_recovery_without_any_info
:reports_with_recovery_without_any_info rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Reports_group ;
                                        OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                                        OpenPVSignal:has_count 2 ;
                                        OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                        OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                                        rdfs:label "reports with recovery without any info" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#reports_with_subcutaneous_administration
:reports_with_subcutaneous_administration rdf:type owl:NamedIndividual ,
                                                   OpenPVSignal:Reports_group ;
                                          OpenPVSignal:is_related_with_drug_intake :Subcutaneous_administration ;
                                          OpenPVSignal:is_subgroup_of :OverallReportsAfterTheEliminationOfDuplicates ;
                                          OpenPVSignal:has_count 7 ;
                                          OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                          rdfs:label "reports with subcutaneous administration" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#rituximab
:rituximab rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Drug ;
           OpenPVSignal:has_ATC_code "L01XC02 " ;
           rdfs:label "rituximab" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#sinusitis
:sinusitis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "J01.90" ;
           OpenPVSignal:has_MedDRA_code 10040753 ;
           OpenPVSignal:has_MedDRA_prefered_term "Sinusitis" ;
           rdfs:label "sinusitis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#skinAtrophy
:skinAtrophy rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_MedDRA_code 10040799 ;
             OpenPVSignal:has_MedDRA_prefered_term "Skin atrophy" ;
             rdfs:label "skin atrophy" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#skinExfoliation
:skinExfoliation rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "L49.1" ;
                 OpenPVSignal:has_MedDRA_code 10040844 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Skin exfoliation" ;
                 rdfs:label "skin exfoliation" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#skinHyperpigmentation
:skinHyperpigmentation rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_ICD_code "L81.9" ;
                       OpenPVSignal:has_MedDRA_code 10040865 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Skin hyperpigmentation" ;
                       rdfs:label "skin hyperpigmentation" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#skinNodule
:skinNodule rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Adverse_Effect ;
            OpenPVSignal:has_MedDRA_code 10040902 ;
            OpenPVSignal:has_MedDRA_prefered_term "Skin nodule" ;
            rdfs:label "skin nodule" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#skinReactionLocalisedAggravated
:skinReactionLocalisedAggravated rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Adverse_Effect ;
                                 OpenPVSignal:has_MedDRA_code 10040915 ;
                                 OpenPVSignal:has_MedDRA_prefered_term "Skin reaction localised" ;
                                 rdfs:label "skin reaction localised" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#skinSwelling
:skinSwelling rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "R22.9" ;
              OpenPVSignal:has_MedDRA_code 10053262 ;
              OpenPVSignal:has_MedDRA_prefered_term "Skin swelling" ;
              rdfs:label "skin swelling" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#stomatitisAphthous
:stomatitisAphthous rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_MedDRA_code 10042131 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Stomatitis aphthous" ;
                    rdfs:label "stomatitis aphthous" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#sulfonamides
:sulfonamides rdf:type owl:NamedIndividual ,
                       OpenPVSignal:DrugClass ;
              OpenPVSignal:has_ATC_code "D06BA " ;
              rdfs:label "sulfonamides" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#sumatriptan
:sumatriptan rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:has_ATC_code "N02CC01 " ;
             rdfs:label "sumatriptan" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#tetracyclines
:tetracyclines rdf:type owl:NamedIndividual ,
                        OpenPVSignal:DrugClass ;
               OpenPVSignal:has_ATC_code "J01A " ;
               rdfs:label "tetracyclines" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#timeToOnsetData
:timeToOnsetData rdf:type owl:NamedIndividual ,
                          time:DurationDescription ;
                 OpenPVSignal:has_content "Time to onset was reported in seven of the reports and ranged from a few days to seven months after the drug was administered with a median of about 3-4 weeks." ;
                 rdfs:label "time to onset data" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#tnf-aAntagonists
:tnf-aAntagonists rdf:type owl:NamedIndividual ,
                           OpenPVSignal:DrugClass ;
                  OpenPVSignal:has_ATC_code "L04AB" ;
                  rdfs:label "TNFa inhibitors" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#toxicEpidermalNecrolysis
:toxicEpidermalNecrolysis rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Adverse_Effect ;
                          OpenPVSignal:has_ICD_code "L51.2" ;
                          OpenPVSignal:has_MedDRA_code 10044223 ;
                          OpenPVSignal:has_MedDRA_prefered_term "toxic epidermal necrolysis " ;
                          rdfs:label "toxic epidermal necrolysis " .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#urinaryTractInfection
:urinaryTractInfection rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Adverse_Effect ;
                       OpenPVSignal:has_ICD_code "N39.0 " ;
                       OpenPVSignal:has_MedDRA_code 10046571 ;
                       OpenPVSignal:has_MedDRA_prefered_term "Urinary tract infection" ;
                       rdfs:label "urinary tract infection" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#urticaria
:urticaria rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "L50.9" ;
           OpenPVSignal:has_MedDRA_code 10046735 ;
           OpenPVSignal:has_MedDRA_prefered_term "Urticaria" ;
           rdfs:label "urticaria" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#usage_for_dosage_3
:usage_for_dosage_3 rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug_Usage ;
                    OpenPVSignal:refers_to_dosage :Dosage_3 ;
                    OpenPVSignal:refers_to_drug :denosumab ;
                    rdfs:label "usage for dosage 3" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#vaginalDisorder
:vaginalDisorder rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Adverse_Effect ;
                 OpenPVSignal:has_ICD_code "N89.8" ;
                 OpenPVSignal:has_MedDRA_code 10061402 ;
                 OpenPVSignal:has_MedDRA_prefered_term "Vaginal disorder" ;
                 rdfs:label "vaginal disorder" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#vaginalHaemorrhage
:vaginalHaemorrhage rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "N93.9" ;
                    OpenPVSignal:has_MedDRA_code 10046910 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Vaginal haemorrhage" ;
                    rdfs:label "vaginal haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#vaginalItching
:vaginalItching rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10046918 ;
                OpenPVSignal:has_MedDRA_prefered_term "Vaginal itching" ;
                rdfs:label "vaginal itching" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#vaginitis
:vaginitis rdf:type owl:NamedIndividual ,
                    OpenPVSignal:Adverse_Effect ;
           OpenPVSignal:has_ICD_code "N76.0" ;
           OpenPVSignal:has_MedDRA_code 10046914 ;
           OpenPVSignal:has_MedDRA_prefered_term "Vaginal infection" ;
           rdfs:label "vaginitis" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#vulvaDisorder
:vulvaDisorder rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "N90.89" ;
               OpenPVSignal:has_MedDRA_code 10047754 ;
               OpenPVSignal:has_MedDRA_prefered_term "Vulval disorder" ;
               rdfs:label "vulva disorder" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#vulvovaginalDiscomfort
:vulvovaginalDiscomfort rdf:type owl:NamedIndividual ,
                                 OpenPVSignal:Adverse_Effect ;
                        OpenPVSignal:has_ICD_code "N89.8" ;
                        OpenPVSignal:has_MedDRA_code 10047786 ;
                        OpenPVSignal:has_MedDRA_prefered_term "Vulvovaginal discomfort" ;
                        rdfs:label "vulvovaginal discomfort" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#vulvovaginalRash
:vulvovaginalRash rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "N89.8" ;
                  OpenPVSignal:has_MedDRA_code 10071588 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Vulvovaginal rash" ;
                  rdfs:label "vulvovaginal rash" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#weightDecrease
:weightDecrease rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_MedDRA_code 10047895 ;
                OpenPVSignal:has_MedDRA_prefered_term "Weight decreased" ;
                rdfs:label "weight decrease" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#6months-intervalBetweenAdministrations
<http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#6months-intervalBetweenAdministrations> rdf:type owl:NamedIndividual ,
                                                                                                                      time:DurationDescription ;
                                                                                                             time:nominalPosition "months" ;
                                                                                                             time:numericPosition 6 ;
                                                                                                             rdfs:label "6 months-interval between administrations" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#ReportsInVigiBase®
<http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#ReportsInVigiBase®> rdf:type owl:NamedIndividual ,
                                                                                                  OpenPVSignal:Free_text_reporting_element ;
                                                                                         OpenPVSignal:has_content "As of 1 January 2016 there are 18 individual case safety reports of LP in association with denosumab in the WHO Global ICSR database, VigiBase® (Table 1). After the elimination of four suspected duplicates, the remaining 14 reports were submitted from the United States (8 reports), Canada, Denmark, Greece, the Netherlands, Serbia and Switzerland (1 report each). The patients ranged in age from 59 to 86 years with a median of 69 years in the 13 reports which provided this information. There were 13 females and the gender was not stated in the remaining report. Denosumab was the only drug suspected in 12 of the 14 cases. Adalimumab was an additional suspected drug in one case and rituximab was an additional suspected drug in another case. Concomitant drugs were reported in 10 of the 14 cases and indicated a patient population with a number of concomitant conditions indicated by the use of calcium (6 patients), drugs for the treatment of stomach acidity (5), vitamin D (4), other vitamins and/or minerals (3), and drugs for treatment of each of hypothyroidism and anxiety (3). Denosumab was reported to have been administered subcutaneously, as expected, in all seven cases which provided the information. The indication for use was stated in 11 reports and was osteoporosis or postmenopausal osteoporosis in all cases. Dosage was reported in seven cases and was 60 mg per six months in three reports, 60 mg without the frequency mentioned in four reports, and two other reports specified one dosage form per six months. Time to onset was reported in seven of the reports and ranged from a few days to seven months after the drug was administered with a median of about 3-4 weeks. The outcome of the LP was stated in six of the 14 reports. All six patients were reported as recovered or recovering. In these patients, the drug was reported as withdrawn in four cases while the outcome of the drug was unknown in the remaining two cases. Other reactions were reported in nine of the 14 cases. These included rashes in five cases, dermatitis, eczema or another skin condition in four cases and pruritus in three cases." ;
                                                                                         rdfs:label "Reports in VigiBase® " .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#ascorbicacid/pyridoxinehydrochloride/biotin/tocopherylacetate/folicacid/cyanocobalamin/retinol/pantothenicacid/riboflavin/phytomenadione/nicotinamide/ferrousnfumarate/thiaminemononitrate/magnesiumoxide/zincoxide/cupricoxide/calcium/potassiumChloride
<http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#ascorbicacid/pyridoxinehydrochloride/biotin/tocopherylacetate/folicacid/cyanocobalamin/retinol/pantothenicacid/riboflavin/phytomenadione/nicotinamide/ferrousnfumarate/thiaminemononitrate/magnesiumoxide/zincoxide/cupricoxide/calcium/potassiumChloride> rdf:type owl:NamedIndividual ,
                                                                                                                                                                                                                                                                                                                                         OpenPVSignal:Drug ;
                                                                                                                                                                                                                                                                                                                                OpenPVSignal:has_ATC_code "A02AA02" ,
                                                                                                                                                                                                                                                                                                                                                          "A11AA02" ,
                                                                                                                                                                                                                                                                                                                                                          "A11CA01" ,
                                                                                                                                                                                                                                                                                                                                                          "A11DA01" ,
                                                                                                                                                                                                                                                                                                                                                          "A11GA01" ,
                                                                                                                                                                                                                                                                                                                                                          "A11HA01" ,
                                                                                                                                                                                                                                                                                                                                                          "A11HA02" ,
                                                                                                                                                                                                                                                                                                                                                          "A11HA03" ,
                                                                                                                                                                                                                                                                                                                                                          "A11HA04" ,
                                                                                                                                                                                                                                                                                                                                                          "A11HA31" ,
                                                                                                                                                                                                                                                                                                                                                          "A12AA" ,
                                                                                                                                                                                                                                                                                                                                                          "A12BA01" ,
                                                                                                                                                                                                                                                                                                                                                          "B02BA01" ,
                                                                                                                                                                                                                                                                                                                                                          "B03AA02" ,
                                                                                                                                                                                                                                                                                                                                                          "B03BA01" ,
                                                                                                                                                                                                                                                                                                                                                          "B03BB01" ,
                                                                                                                                                                                                                                                                                                                                                          "C05AX04" ,
                                                                                                                                                                                                                                                                                                                                                          "R06AA59" ;
                                                                                                                                                                                                                                                                                                                                rdfs:label "ascorbic acid/ pyridoxine hydrochloride/ biotin/ tocopheryl acetate/ folic acid/ cyanocobalamin/ retinol/ pantothenic acid/ riboflavin/ phytomenadione/ nicotinamide/ ferrousnfumarate/ thiamine mononitrate/ magnesium oxide/ zinc oxide/ cupric oxide/ calcium/ potassium chloride" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcarbonate/calciumLactateGluconate
<http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcarbonate/calciumLactateGluconate> rdf:type owl:NamedIndividual ,
                                                                                                                        OpenPVSignal:Drug ;
                                                                                                               OpenPVSignal:has_ATC_code "A12AA06" ;
                                                                                                               rdfs:label "calcium carbonate/calcium lactate gluconate" .


###  http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcitrate/Magnesium
<http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcitrate/Magnesium> rdf:type owl:NamedIndividual ,
                                                                                                        OpenPVSignal:Drug ;
                                                                                               OpenPVSignal:has_ATC_code "A12AX" ;
                                                                                               rdfs:label "calcium citrate/ magnesium" .


#################################################################
#    Annotations
#################################################################

<http://purl.org/OpenPVSignal/Signals/2016_6_denosumab_lichen_planus#calciumcitrate/magnesium> rdfs:label "calcium citrate/magnesium" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
